LIFR Human

Leukemia Inhibitory Factor Receptor Alpha Human Recombinant
Shipped with Ice Packs
In Stock

Description

Introduction to LIFR Human

The Leukemia Inhibitory Factor Receptor (LIFR) is a transmembrane protein encoded by the LIFR gene in humans. It functions as a critical component of cytokine signaling, forming heterodimeric complexes with glycoprotein 130 (gp130) to mediate responses to ligands such as Leukemia Inhibitory Factor (LIF), Oncostatin M (OSM), and Ciliary Neurotrophic Factor (CNTF) . LIFR is essential for regulating cellular processes, including stem cell pluripotency, bone metabolism, and neural development, while its dysregulation is implicated in cancer progression and congenital disorders .

Stem Cell Regulation

LIFR signaling maintains embryonic stem cell (ESC) pluripotency via STAT3 activation. In humans, LIF binding to LIFR/gp130 prevents spontaneous differentiation, enabling long-term ESC culture .

Neural and Autonomic Development

LIFR is critical for autonomic nervous system development, regulating processes like breathing and thermoregulation. Knockout models exhibit severe neural defects and neonatal lethality .

Bone and Immune Modulation

LIFR influences osteoblast differentiation and bone remodeling. It also modulates immune responses by regulating macrophage polarization and T-cell activity .

Role in Cancer: Dual Functions

LIFR exhibits context-dependent roles in cancer progression:

Pan-cancer analyses reveal LIFR’s prognostic value, with high expression improving survival in kidney (KIRC, KIRP) and lung (LUAD) cancers but worsening outcomes in stomach (STAD) and adrenal (ACC) cancers .

Congenital Disorders

Mutations in LIFR cause Stüve-Wiedemann Syndrome (SWS), characterized by skeletal dysplasia, autonomic dysfunction, and respiratory failure .

Therapeutic Targeting

EC359, a small-molecule LIFR inhibitor, demonstrates efficacy in preclinical models:

  • Induces ferroptosis in ovarian cancer cells .

  • Reduces tumor growth in xenograft models (e.g., 60% inhibition in PDX models) .

  • Synergizes with chemotherapy to overcome drug resistance .

Other strategies include monoclonal antibodies against LIFR and soluble decoy receptors to block ligand binding .

Research Gaps and Future Directions

  1. Mechanistic Insights: Clarify LIFR’s dual roles in tumor suppression vs. promotion.

  2. Biomarker Development: Validate LIFR expression as a prognostic tool across cancer subtypes.

  3. Therapeutic Optimization: Improve the pharmacokinetics and specificity of LIFR-targeted drugs.

Product Specs

Introduction
The leukemia inhibitory factor receptor (LIFR) is a protein that binds to leukemia inhibitory factor (LIF). LIF is a cytokine that plays a role in the development and function of many different cell types. LIFR is important for the implantation of the embryo in the uterus during pregnancy.
Description
This product is a solution of LIFR protein that has been purified from Sf9 insect cells. The protein is glycosylated, meaning that it has sugars attached to it. The molecular weight of the protein is 90.5 kDa, but it appears as a band between 100 and 150 kDa on SDS-PAGE. The protein has a 6-amino acid His tag at its C-terminus.
Physical Appearance
This product is a clear, colorless liquid that has been sterilized by filtration.
Formulation
This product is supplied as a 0.5 mg/ml solution of LIFR protein in phosphate-buffered saline (pH 7.4) containing 10% glycerol.
Stability
This product should be stored at 4°C if it will be used within 2-4 weeks. For longer-term storage, the product should be stored at -20°C. It is recommended to add a carrier protein (0.1% HSA or BSA) for long-term storage. Avoid repeated freezing and thawing of the product.
Purity
The purity of this product is greater than 90% as determined by SDS-PAGE.
Synonyms
Leukemia Inhibitory Factor Receptor Alpha, CD118 Antigen, LIF Receptor, LIF-R, Leukemia Inhibitory Factor Receptor, CD118, SJS2, STWS, SWS, Leukemia inhibitory factor receptor, LIF receptor, LIF-R.
Source
Sf9, Baculovirus cells.
Amino Acid Sequence
ADPQKKGAPH DLKCVTNNLQ VWNCSWKAPS GTGRGTDYEV CIENRSRSCY QLEKTSIKIP ALSHGDYEIT INSLHDFGSS TSKFTLNEQN VSLIPDTPEI LNLSADFSTS TLYLKWNDRG SVFPHRSNVI WEIKVLRKES MELVKLVTHN TTLNGKDTLH HWSWASDMPL ECAIHFVEIR CYIDNLHFSG LEEWSDWSPV KNISWIPDSQ TKVFPQDKVI LVGSDITFCC VSQEKVLSAL IGHTNCPLIH LDGENVAIKI RNISVSASSG TNVVFTTEDN IFGTVIFAGY PPDTPQQLNC ETHDLKEIIC SWNPGRVTAL VGPRATSYTL VESFSGKYVR LKRAEAPTNE SYQLLFQMLP NQEIYNFTLN AHNPLGRSQS TILVNITEKV YPHTPTSFKV KDINSTAVKL SWHLPGNFAK INFLCEIEIK KSNSVQEQRN VTIKGVENSS YLVALDKLNP YTLYTFRIRC STETFWKWSK WSNKKQHLTT EASPSKGPDT WREWSSDGKN LIIYWKPLPI NEANGKILSY NVSCSSDEET QSLSEIPDPQ HKAEIRLDKN DYIISVVAKN SVGSSPPSKI ASMEIPNDDL KIEQVVGMGK GILLTWHYDP NMTCDYVIKW CNSSRSEPCL MDWRKVPSNS TETVIESDEF RPGIRYNFFL YGCRNQGYQL LRSMIGYIEE LAPIVAPNFT VEDTSADSIL VKWEDIPVEE LRGFLRGYLF YFGKGERDTS KMRVLESGRS DIKVKNITDI SQKTLRIADL QGKTSYHLVL RAYTDGGVGP EKSMYVVTKE NSHHHHHH.

Q&A

How do I determine if my study involves human participants?

To determine if your study involves human participants, you must evaluate whether your research directly engages with living individuals about whom you will obtain data through intervention or interaction, or will collect identifiable private information. This assessment is the first critical step in determining what research policies and ethical guidelines apply to your work .

Human participants research includes studies where individuals are prospectively assigned to specific conditions or interventions and data about their responses or outcomes are collected. This encompasses a wide range of approaches from observational studies to randomized controlled trials .

What differentiates a clinical trial from other human research?

A clinical trial is defined as "a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes" . To determine if your human research qualifies as a clinical trial, ask these four key questions:

  • Does the study involve human participants?

  • Are the participants prospectively assigned to an intervention?

  • Is the study designed to evaluate the effect of the intervention on the participants?

  • Is the effect being evaluated a health-related biomedical or behavioral outcome?

If you answer yes to all four questions, your research is considered a clinical trial, which encompasses a wide spectrum of study types from mechanistic and behavioral studies to pilot/feasibility studies and large-scale efficacy trials .

What are the fundamental experimental designs for human subjects research?

Two principal experimental designs exist for human subjects research:

Within-subjects design: Participants serve as their own controls by participating in both control and experimental conditions. This approach significantly reduces variation due to individual differences, as the same subjects are measured before and after manipulation of the independent variable .

For example, in pharmaceutical studies, a group might first receive a placebo (control condition) and later receive the experimental drug, with differences in measurements attributed to the drug's effects .

Between-subjects design: Different groups of participants are assigned to different experimental conditions. While this design avoids certain problems of within-subjects designs (like carryover effects), it requires careful attention to participant assignment to ensure group equivalence .

How do I establish proper experimental controls in human research?

Experimental controls establish a baseline for comparison and are essential for determining if changes in the dependent variable result from manipulating the independent variable rather than from extraneous factors .

For human subject experiments, controls may take two forms:

  • A separate control group not exposed to the independent variable manipulation

  • The same participants measured before and after altering the independent variable (within-subjects design)

To strengthen controls, consider implementing:

  • Placebo controls: To account for psychological effects of simply receiving an intervention

  • Attention controls: To ensure groups receive equivalent attention from researchers

  • Randomization: To distribute participant characteristics evenly across conditions

What ethical considerations are fundamental to human subjects research?

Ethical considerations must be integrated throughout the research process. Key elements include:

  • Obtaining informed consent: Participants must understand the nature of the research, potential risks and benefits, and their right to withdraw

  • Protecting privacy and confidentiality: Safeguarding identifiable information

  • Minimizing potential harm: Both physical and psychological

  • Ensuring fair participant selection: Avoiding exploitation of vulnerable populations

  • Maintaining scientific integrity: Using rigorous methods and honestly reporting results

Before initiating any human subjects research, obtain proper institutional review board (IRB) approval and ensure all researchers complete required ethical training .

How can I address the limitations of correlational research in human studies?

Correlational research faces two primary limitations when studying human subjects:

Direction of cause and effect: Correlation identifies relationships but doesn't establish which variable causes changes in the other. To address this limitation:

  • Implement time-sequence designs where possible (measure the presumed cause before the effect)

  • Use statistical techniques like cross-lagged panel correlation

  • Consider supplementing with experimental methods when ethically feasible

The third-variable problem: Correlations may result from unmeasured variables influencing both measured variables. Strategies to address this include:

  • Statistical control techniques (e.g., partial correlation, multiple regression)

  • Matching participants on potential confounding variables

  • Measuring and accounting for potential third variables in your analysis

While correlational methods are valuable for prediction and establishing relationships, understanding these limitations is critical for appropriate interpretation and avoiding causal claims when not warranted .

What methodologies are most appropriate for developmental human research?

Human developmental research employs several specialized methodologies, each with distinct advantages:

Cross-sectional research: Studies different age groups simultaneously. While efficient, this approach can confound age effects with cohort differences (historical experiences of different generations) .

Longitudinal research: Follows the same participants over time. This method directly measures intra-individual change but faces challenges including participant attrition, practice effects, and time investment .

Sequential designs: Combine aspects of both approaches to overcome their respective limitations:

  • Cross-sequential design: Studies multiple age cohorts at multiple measurement points

  • Cohort-sequential design: Examines multiple cohorts as they enter the same age range

  • Time-sequential design: Measures different cohorts at the same age but at different times

The selection among these designs should be guided by research questions, resources, and practical constraints of time and participant availability.

How can I effectively select dependent measures in human research?

The selection of dependent measures requires careful consideration of multiple factors:

Sensitivity: Choose measures capable of detecting the effects you're studying, even when those effects might be subtle. This may involve:

  • Using multiple measures to capture different aspects of the dependent variable

  • Selecting measures with appropriate ranges to avoid ceiling or floor effects

  • Ensuring measures are sensitive to the specific populations being studied

Multiple measures approach: Implement several dependent measures to:

  • Capture different dimensions of the outcome

  • Provide converging evidence across measurement types

  • Increase the likelihood of detecting effects that might manifest differently across measures

Cost considerations: Balance ideal measurement with practical constraints:

  • Time requirements for administration and scoring

  • Participant burden and fatigue

  • Financial costs of standardized measures or specialized equipment

  • Training requirements for administrators

The most effective measurement approach typically employs multiple measures selected based on theoretical relevance, psychometric properties, and practical feasibility.

How do I control for experimenter expectancy effects in human research?

Experimenter expectancies can unintentionally influence participants' responses, threatening research validity. Advanced techniques to control these effects include:

Blind procedures: Ensuring that those who interact with participants are unaware of:

  • The experimental condition to which participants are assigned

  • The specific hypotheses being tested

  • Previous measurements or expected outcomes

Double-blind designs: Neither the participants nor the individuals administering interventions or collecting data know which experimental condition is being implemented .

Standardized protocols: Develop detailed scripts and procedures that:

  • Minimize improvisation or variation in participant interactions

  • Specify exact wording for instructions

  • Detail precisely how measures should be administered and scored

Automated data collection: When possible, use computerized or automated measurement systems that reduce direct experimenter-participant interaction during critical data collection phases .

What approaches strengthen quasi-experimental designs when randomization is not possible?

When random assignment is not feasible (due to ethical constraints, practical limitations, or naturally occurring groups), several strategies can strengthen quasi-experimental designs:

Nonequivalent control group design: Uses a comparison group that resembles the experimental group but wasn't randomly assigned. Strengths can be enhanced by:

  • Collecting detailed demographic and relevant background information

  • Statistically controlling for pre-existing differences

  • Matching participants across groups on key variables

One-group pretest-posttest design: Measures the same participants before and after an intervention. This design can be improved by:

  • Adding multiple baseline measurements to establish stability before intervention

  • Implementing multiple posttest measurements to assess persistence of effects

  • Including follow-up measurements to evaluate long-term outcomes

Time series designs: Collect multiple measurements before and after intervention to distinguish intervention effects from natural fluctuations or trends. This approach is particularly valuable when populations are their own controls .

Mixed-methods approach: Combine quantitative measurements with qualitative data (interviews, observations) to provide contextual understanding and alternative perspectives on intervention effects .

What methodological adaptations are necessary when conducting research with children?

Research with children requires specialized methodological approaches that account for developmental capabilities and ethical considerations:

Age-appropriate measures: Select or adapt assessment tools that:

  • Match cognitive and linguistic abilities of the specific age group

  • Use concrete rather than abstract concepts for younger children

  • Employ engaging formats to maintain attention and motivation

Observational techniques: Often more appropriate than self-report for younger children, including:

  • Structured play scenarios

  • Behavioral coding systems

  • Parent-child interaction assessments

Ethical safeguards: Implement additional protections beyond standard human subjects protocols:

  • Obtaining parental/guardian consent plus child assent when appropriate

  • Heightened vigilance for signs of discomfort or distress

  • Reduced session durations to prevent fatigue

Developmental sensitivity: Research design must account for rapid developmental changes:

  • More frequent assessment points for longitudinal studies

  • Narrower age bands for cross-sectional comparisons

  • Careful interpretation of findings within developmental context

How can single-subject designs be effectively implemented in human research?

Single-subject designs offer powerful methodological approaches for studying intervention effects in individuals, particularly valuable in clinical, educational, and rehabilitation research:

Reversal designs (A-B-A-B): The participant experiences baseline conditions (A), followed by intervention (B), withdrawal of intervention (return to A), and reintroduction of intervention (B). This design:

  • Establishes experimental control by demonstrating that behavior changes correspond with intervention phases

  • Demonstrates intervention effects multiple times within the same participant

  • Addresses concerns about coincidental changes unrelated to intervention

Multiple baseline designs: Intervention is introduced at different times across:

  • Multiple participants

  • Multiple behaviors in the same participant

  • Multiple settings for the same behavior

This approach:

  • Demonstrates intervention effects while avoiding ethical concerns of withdrawing effective interventions

  • Controls for history effects (external events) by staggering intervention timing

  • Shows specificity of effects to targeted behaviors/settings

For maximum validity, these designs require:

  • Stable baseline measurements before intervention

  • Systematic, objective measurement procedures

  • Sufficient data points in each phase to establish patterns

  • Careful attention to treatment integrity (consistent implementation)

How is human subjects research methodology evolving?

Human subjects research methodology continues to evolve in response to new technologies, ethical considerations, and scientific understanding. Key developments include:

Integration of mixed methods: Combining quantitative and qualitative approaches to provide complementary insights, with increasing recognition that different questions may require different methodological toolkits .

Technological advancements: Implementation of digital data collection, wearable sensors, and remote monitoring that allow for:

  • More naturalistic observation

  • Continuous rather than discrete measurement

  • Reduced participant burden in longitudinal studies

Participatory research models: Growing emphasis on including participants as collaborators in research design, implementation, and interpretation rather than merely as subjects of study .

Transparency initiatives: Movement toward pre-registration of study designs, open methods, and data sharing to enhance replicability and cumulative knowledge .

As research questions become increasingly complex, methodological approaches will continue to adapt, combining established techniques with innovative methods to advance understanding of human behavior, development, and health.

Product Science Overview

Introduction

Leukemia Inhibitory Factor Receptor Alpha (LIFRα), also known as CD118, is a crucial component of the cytokine receptor family. It plays a significant role in mediating the biological effects of various cytokines, including Leukemia Inhibitory Factor (LIF), Cardiotrophin-1, and Oncostatin M . This receptor is essential for numerous physiological processes, including cell differentiation, proliferation, and survival.

Structure and Expression

LIFRα is a type I transmembrane protein with a molecular weight of approximately 190 kDa . It forms a high-affinity receptor complex with gp130, a common signal transducing subunit shared by all members of the IL-6 cytokine family . This complex is responsible for activating downstream signaling pathways, such as the JAK/STAT and MAPK cascades .

LIFRα is expressed in various tissues throughout the body, including the trophectoderm of the developing embryo . Its expression is crucial for the maintenance of pluripotency in embryonic stem cells, as it promotes self-renewal by recruiting signal transducer and activator of transcription 3 (Stat3) .

Biological Functions

LIFRα mediates the effects of LIF, which is known for its ability to induce the terminal differentiation of myeloid leukemic cells . This receptor is involved in several physiological processes, including:

  • Cell Growth and Differentiation: LIFRα influences the growth and differentiation of various cell types, including hematopoietic, neuronal, and embryonic stem cells .
  • Bone Metabolism: It plays a role in bone metabolism by affecting the differentiation and activity of osteoblasts and osteoclasts .
  • Inflammation and Immune Response: LIFRα is involved in the regulation of inflammatory responses and the synthesis of acute-phase proteins .
  • Neural Development: It contributes to neural development by promoting the survival and differentiation of neural cells .
Recombinant Human LIFRα

Recombinant human LIFRα is produced using mammalian expression systems to ensure proper folding and post-translational modifications . This recombinant protein is used in various research applications, including stem cell culture, where it supports the maintenance of pluripotency and self-renewal .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.